- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01338025
Evaluation of 3TC or FTC Mono-therapy Compared to Continuing HAART as a Bridging Strategy (P1094)
Evaluation of 3TC or FTC Mono-therapy Compared to Continuing HAART as a Bridging Antiretroviral Strategy in Persistently Non-adherent Children, Adolescents, and Young Adults Who Are Failing HAART and Have the M184V Resistance Mutation.
The purpose of this study was to compare the use of lamivudine (3TC) or emtricitabine (FTC) alone vs. continuing a failing highly active antiretroviral therapy (HAART) regimen in HIV infected children, adolescents and young adults. The study was to see if there were changes in the HIV virus and if there were differences in immune function, viral load and medication side effects between the two groups over 28 weeks. Participants were assigned to either take 3TC or FTC alone or continue on his/her current failing HAART regimen. During the first 28 weeks of this study, if the participant was randomized to the continue HAART arm, he/she was not switched to a different or new, potentially suppressive HAART regimen, but continued on the current failing HAART regimen. However, if continuing HAART, the participant might be switched to a new regimen if their provider felt that it was clinically needed or the participant met certain study endpoints (e.g., drop in CD4, increase in viral load).
At the end of 28 weeks, the participant had the choice of remaining on the assigned study group medication(s) or starting a new HAART regimen prescribed by his/her doctor. Then, they would be followed for another 24 weeks to compare the difference in immune function, viral load and medication side effects between the different groups.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Currently, there is no clear consensus for managing virologic failure. Generally, failure of non-nucleoside reverse transcriptase inhibitor (NNRTI)-based therapy due to non-adherence is associated with high rates of NNRTI resistance, while failure of protease inhibitor (PI)-based therapy due to non-adherence carries a much lower risk of PI resistance. In the setting of incomplete adherence and virologic failure despite adherence education, an optimal strategy would be one that effectively bridges the period between the cessation of the failing regimen of highly active antiretroviral (ARV) therapy and initiation of a new HAART regimen. This would provide time for interventions to improve adherence to be effective while minimizing accumulation of additional drug resistance mutations. Given the compelling need for an effective bridging strategy, the limited evidence for the safety and efficacy of this bridging regimen, and the high level of acceptability of studying 3TC or FTC monotherapy as an effective alternative, P1094 proposed to conduct a randomized clinical trial (RCT) comparing use of 3TC or FTC monotherapy as a short-term bridging regimen vs. continuation of non-suppressive HAART in non-adherent subjects.
This study closed early due to lack of accrual, with only 33 of the target 344 participants enrolled. Therefore analyses, including the analysis of the primary outcome, are descriptive. Only analyses for Step 1 could be done (Step 2 was observational). The following secondary analyses could not be performed:
Changes in Genotypic HIV Drug Resistance From Baseline Changes HIV Replication Capacity [Time Frame: 28 and 52 weeks] Changes in CD4 Percent and CD4+ T Cell Count [Time Frame: 52 weeks] Changes in HIV-1 RNA Levels [Time Frame: 52 Weeks] Changes in Immune Activation [Time Frame: 28 and 52 Weeks] Number and Percent of Subjects With Adverse Clinical Outcomes [Time Frame: 52 Weeks] Adherence as Measured by 3-day Recall [Time Frame: 52 Weeks]
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Buenos Aires, Argentina, C1221ADC
- Hospital General de Agudos Buenos Aires Argentina NICHD CRS (5082)
-
-
-
-
-
Rio de Janeiro, Brazil, 26030
- Hospital Geral De Nova Igaucu Brazil NICHD CRS (5097)
-
Sao Paulo, Brazil, 01246-900
- Insituto de Infectologia Emilio Ribas NICHD CRS (5075)
-
Sao Paulo, Brazil, 14049-900
- Univ of Sao Paulo Brazil NICHD CRS (5074)
-
-
-
-
-
San Juan, Puerto Rico, 00936-5067
- University of Puerto Rico Pediatric HIV/AIDS Research (6601)
-
-
-
-
-
Chiang Mai, Thailand, 50200
- Chiang Mai University Pediatrics-Obstetrics CRS (20101)
-
-
Ratchathewi,
-
Bangkok, Ratchathewi,, Thailand, 10700
- Siriraj Hospital Mahidol University CRS (8251)
-
-
-
-
California
-
San Francisco,, California, United States, 94117
- Univ. of California San Francisco NICHD CRS (5091)
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Children's National Med. Ctr. Washington DC NICHD CRS (5015)
-
-
Florida
-
Jacksonville, Florida, United States, 32209
- University of Florida (5051)
-
Miami, Florida, United States, 33136
- Univ of Miami Pediatric/Perinatal HIV/AIDS (4201)
-
-
Illinois
-
Chicago, Illinois, United States, 60614
- Chicago Children's CRS (4001)
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins University NICHD CRS (5092)
-
-
New York
-
Bronx, New York, United States, 10457
- Bronx-Lebanon Hospital (6901)
-
New York, New York, United States, 10029
- Metropolitan Hospital (5003)
-
Stony Brook, New York, United States, 11794
- SUNY Stony Brook NICHD CRS (5040)
-
-
North Carolina
-
Durham, North Carolina, United States, 27710-3499
- DUMC Ped. CRS (4701)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Step 1 Inclusion Criteria:
- Age greater than or equal to 8 to less than 25 years of age, at study entry
- Documentation of HIV-1 infection defined as positive results from two samples collected at different time points
- Treatment experienced patients must have demonstrated failure on the current HAART regimen for 2 months or longer. These patients must have been on ARVs for at least a total of 6 months prior to entry. Thus, if the failing regimen was the first ARV regimen, then the patient must have been on that initial regimen for a minimum of 6 months total.
- CD4+ T cell count greater than or equal to 100 cells/mm3 (confirmed on at least two occasions within 6 months of study entry, including the screening value)
- Documentation of the M184V mutation on genotypic testing at any time prior to study entry
- In the best judgment of the clinical site team, concerns about the subject's ability to adhere made it unsuitable to initiate a new optimal HAART regimen for at least 6 months.
- Subject had not become adherent despite site's adherence interventions
- Female subjects of reproductive potential engaging in sexual activity that could lead to pregnancy had to agree to avoid pregnancy during the entire 52 week trial and to consistently and appropriately use at least two of the following contraception methods: condoms, diaphragm or cervical cap with spermicide, IUD, hormonal-based contraception. A list of acceptable methods can be found at the FDA Birth Control Guide (http://www.fda.gov/womens).
- Parent/legal guardian or subject able and willing to provide signed informed consent when applicable
Step 1 Exclusion Criteria:
- Positive hepatitis B surface antigen or known active hepatitis B infection.
- Pregnant or breastfeeding.
- Active malignancy within the past 2 years.
- Current immunosuppressive therapy, including the equivalent of greater than 1 mg/kg/per day or greater than 20 mg total daily dose of prednisone in the 2 weeks preceding screening. Subjects for whom long-term systemic corticosteroid therapy (greater than 2 weeks) was anticipated were excluded. [Note: non-steroidal anti-inflammatory agents and inhaled, nasal, and topical corticosteroids were not excluded as immunosuppressive therapy.]
- Prior immunization with an HIV-specific vaccine
- Greater than or equal to 1 CDC class C event within the past 12 months.
- Renal disease (as defined by estimated creatinine clearance less than 50 mL/min/1.73m2 confirmed on two occasions within 3 months of screening).
- Active opportunistic infections, including active tuberculosis (TB).
- Current treatment for active systemic TB. If recent, infection must have completed treatment course. INH treatment for latent TB is allowed.
- Viral load greater than 250,000 copies/mL at screening.
- Known greater than or equal than Grade 3 of any of the following laboratory toxicities within 30 days prior to study entry: neutrophil count, hemoglobin, platelets, AST, ALT, lipase, serum creatinine. Note: Subjects could be re-screened and enrolled if repeat value was less than Grade 3 without signs or symptoms of related organ dysfunction.
- Known greater than or equal to Grade 4 laboratory toxicities within 30 days prior to study entry, except with approval of the study team.
- For subjects who were not taking 3TC or FTC at the time of screening: Documented prior intolerance or adverse effect reasonably attributed to 3TC or FTC that resulted in permanent discontinuation.
- Problems with non-adherence attributed to modifiable structural barriers, such as lack of resources (e.g., insurance, transportation).
Step 2 - Inclusion Criteria
- Met requirements for completion of Step 1
- Subject/guardian agree to continue participation in Step 2
- ViroSeq assay results had been received by site and reviewed by investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm A, non-suppressive HAART regimen
In Step 1, subjects were randomized to continue their non-suppressive HAART regimen. In Step 2, subjects either began a new HAART regimen, continued randomized treatment, or discontinued therapy while remaining on follow-up, as decided by their provider. |
The study participant continued their non-suppressive HAART regimen as prescribed by their primary provider.
Other Names:
|
Active Comparator: Arm B, 3TC or FTC monotherapy
In step 1, subjects were randomized to receive 3TC or FTC (the choice of 3TC or FTC was left to the provider). In Step 2, subjects either began a new HAART regimen, continued randomized treatment, or discontinued therapy while remaining on follow-up, as decided by their provider. |
The study participant was assigned to either 3TC or FTC monotherapy (the choice of 3TC or FTC was left to the provider.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Immunologic Deterioration
Time Frame: From entry to week 28
|
Immunologic deterioration was declared for a participant if any one of the following conditions is observed within the first 28 weeks:
Results report number of participants with immunologic deterioration at week 28 calculated. |
From entry to week 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in CD4+ T Cell Count
Time Frame: Entry to week 28
|
Change in CD4+ T cell count from entry to Week 28 (CD4+ at entry - CD4+ at Week 28).
|
Entry to week 28
|
Change in HIV-1 RNA Levels
Time Frame: 28 Weeks
|
Change in HIV-1 RNA levels from Entry to Week 28
|
28 Weeks
|
Number of Participants Non-adherent as Measured by 3-day Recall
Time Frame: 28 Weeks
|
Number of participants reporting a missed medication dose in the past 3 days.
|
28 Weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Allison L. Agwu, MD, Sc.M., Johns Hopkins University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Slow Virus Diseases
- HIV Infections
- Acquired Immunodeficiency Syndrome
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Emtricitabine
- Lamivudine
Other Study ID Numbers
- IMPAACT P1094
- U01AI068632 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Disease
-
University of WashingtonNational Institute of Allergy and Infectious Diseases (NIAID); National Center...Enrolling by invitationInflammation | HIV | HIV-1-infection | HIV Disease ProgressionUnited States
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
Instituto Nacional de Ciencias Medicas y Nutricion...University of Pennsylvania; University of Witwatersrand, South Africa; Case Western... and other collaboratorsUnknownHIV Infections | HIV | Immune Reconstitution Inflammatory SyndromeMexico, United States, South Africa
-
Sarah Kessler, PhD, MPHEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedHIVUnited States, Kenya
-
Merck Sharp & Dohme LLCCompleted
-
Sociedad Andaluza de Enfermedades InfecciosasConsejeria de Salud. Junta de Andalucia. SpainCompletedHIV Infection | HIV-1 InfectionSpain
-
Allegheny Singer Research Institute (also known...Active, not recruitingHIV Infections | HIV-1-infection | HIV I InfectionUnited States
-
TheratechnologiesVanderbilt University Medical Center; Medpace, Inc.; Dacima Consulting; EchosensCompletedLiver Diseases | BMI | Liver Fat | HIV | NAFLD | Hepatic Fibrosis | Hepatic Steatosis | HIV-1-infection | Liver Fibrosis | NASH | HIV Lipodystrophy | HIV-Associated Lipodystrophy | HIV I Infection | Waist Circumference | HIV Infection Primary | HIV Disease Progression | HIV-Infections | Lipohypertrophy | Ectopic FatUnited States
-
University of Alabama at BirminghamGlaxoSmithKlineCompletedHIV Infections | HIVUnited States
Clinical Trials on HAART regimen
-
Danish HIV Research GroupOdense University Hospital; Aarhus University Hospital; Rigshospitalet, Denmark; Hvidovre University Hospital and other collaboratorsUnknownHIV-Associated Lipodystrophy SyndromeDenmark
-
National Institute of Allergy and Infectious Diseases...Completed
-
University of North Carolina, Chapel HillNational Institute on Drug Abuse (NIDA); National Institute of Mental Health...Completed
-
National Institute of Diabetes and Digestive and...CompletedHIV Infection | Chronic Kidney FailureUnited States
-
Hospital Nossa Senhora da ConceicaoCompleted
-
The HIV Netherlands Australia Thailand Research...Chulalongkorn University; National Health Security Office, ThailandCompletedT Cell Response to Asthma in HIV-infected Patients Before and After Starting TreatmentThailand
-
Kaohsiung Medical University Chung-Ho Memorial...Completed
-
Biostable Science & EngineeringCompletedAortic InsufficiencyGermany, Czech Republic
-
Biostable Science & EngineeringCompleted
-
Biostable Science & EngineeringCompleted